#Sweden #Lund #Hansa Biopharma #imlifidase #SwedenBIO

Hansa Biopharma Wins 2025 SwedenBIO Award

In a remarkable achievement, Hansa Biopharma AB has received the esteemed 2025 SwedenBIO Award, distinguishing itself amongst a myriad of accomplished nominees. This accolade was conferred during the SwedenBIO Summit held in Stockholm on January 21, marking a significant milestone for the company. The award acknowledges Hansa’s outstanding contributions to scientific advancement and operational excellence within the healthcare sector.

Hansa Biopharma, traded on Nasdaq Stockholm under the ticker symbol HNSA, has been at the forefront of biotechnology since its establishment in 2007. The SwedenBIO Award, now in its fifteenth year, aims to celebrate companies that are not only achieving scientific milestones but also transforming those achievements into impactful global medical solutions. This year's selection highlights Hansa for converting Sweden’s renowned scientific expertise into significant international health contributions, effectively enhancing life-saving transplantation solutions through its pioneering enzyme technology.

The recognition is particularly poignant given Hansa's focus on supporting highly sensitized patients who have previously faced unreachable medical needs. By leveraging groundbreaking innovations and consistent strong clinical outcomes, Hansa has been instrumental in putting Sweden on the map as a pivotal player in life sciences.

Hansa Biopharma’s CEO, Renée Aguiar-Lucander, expressed her pride and gratitude upon receiving the award. She stated, "I am truly delighted and deeply honored to receive this award on behalf of everyone at Hansa Biopharma. This recognition reflects the great momentum we've built heading into 2026—powered by our strong U.S. Phase 3 data, the upcoming FDA review process, and the anticipated Phase 3 readout from our European trial later this year. Thank you to the SwedenBIO organization and judges for this recognition. We're proud of how far we've come, and excited for the journey ahead."

Hansa's groundbreaking enzyme technology focuses on delivering therapies that address significant unmet medical needs, particularly in the field of transplantation. The company's flagship therapy, imlifidase, stands as a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme that enables kidney transplantation for patients who are highly sensitized. In addition, Hansa is advancing HNSA-5487, a next-generation IgG-cleaving molecule aimed at treating Guillain-Barré Syndrome (GBS).

As Hansa Biopharma continues to innovate and expand its portfolio of therapies across Europe and the United States, the company remains committed to uplifting patient care and transforming the landscape of healthcare for individuals with complex immune disorders. The prospect of growing its influence and improving global health outcomes underscores Hansa Biopharma’s role as a trailblazer in the biopharmaceutical industry.

As they move forward, Hansa Biopharma aims to maintain its trajectory of growth and innovation, leading to breakthroughs in immunomodulatory therapies that have the potential to revolutionize treatment for diverse patient populations. For more information about Hansa Biopharma and its commitment to medical advancement, visit their official website.

In summary, the 2025 SwedenBIO Award is not only a testament to Hansa Biopharma's achievements but also a reflection of the company's bold vision for the future of medicine, inspiring ongoing innovation and dedication in the biopharmaceutical landscape.